Cerebrospinal Fluid γ-Aminobutyric Acid Correlation with Cerebrospinal Fluid and Blood Constituents and Alterations in Neurological Disorders

1980 ◽  
pp. 189-196 ◽  
Author(s):  
S. J. Enna ◽  
Michael G. Ziegler ◽  
C. Raymond Lake ◽  
James H. Wood ◽  
Benjamin Rix Brooks ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Neurological Disorders ◽  
Aminobutyric Acid ◽  
Blood Constituents

Cerebrospinal Fluid  -Aminobutyric Acid Variations in Neurological Disorders

1977 ◽  
Vol 34 (11) ◽  
pp. 683-685 ◽  
Author(s):  
S. J. Enna ◽  
L. Z. Stern ◽  
G. J. Wastek ◽  
H. I. Yamamura
Keyword(s):  
Cerebrospinal Fluid ◽  
Neurological Disorders ◽  
Aminobutyric Acid

Cerebrospinal fluid γ-aminobutyric acid levels in dogs with chronic portosystemic encephalopathy

1986 ◽  
Vol 71 (6) ◽  
pp. 749-753 ◽  
Author(s):  
J. E. Maddison ◽  
D. Yau ◽  
P. Stewart ◽  
G. C. Farrell
Keyword(s):  
Cerebrospinal Fluid ◽  
Aminobutyric Acid ◽  
Plasma Ammonia ◽  
Portosystemic Encephalopathy ◽  
Dog Model ◽  
Csf Levels ◽  
Neurological Features ◽  
The Brain ◽  
Biochemical Abnormalities

1. Cerebrospinal fluid (CSF) γ-aminobutyric acid (GABA) levels were measured in a dog model of spontaneous chronic portosystemic encephalopathy. 2. Dogs with congenital portacaval shunts (intra- or extra-hepatic) develop neurological features of abnormal psychomotor behaviour and depressed consciousness that are consistent with the symptoms of chronic portosystemic encephalopathy in humans. In the five dogs studied, plasma ammonia was elevated, as was CSF tryptophan, both usual biochemical abnormalities in portosystemic encephalopathy. 3. CSF levels of GABA in five dogs with portosystemic encephalopathy (100 ± 13 pmol/ml) were not significantly different from those in five control dogs (96 ± 14 pmol/ml). CSF levels of GABA were not altered after ammonia infusion. 4. If enhanced GABA-ergic neurotransmission, due to influx of gut-derived GABA into the brain, is responsible for the pathophysiology of chronic portosystemic encephalopathy in this model, it is not reflected by increased levels of GABA in CSF.

scholarly journals Neurochemical Effects of 4-(2Chloro-4-Fluorobenzyl)-3-(2-Thienyl)-1,2,4-Oxadiazol-5(4H)-One in the Pentylenetetrazole (PTZ)-Induced Epileptic Seizure Zebrafish Model

2021 ◽  
Vol 22 (3) ◽  
pp. 1285
Author(s):  
Seong Soon Kim ◽  
Hyemin Kan ◽  
Kyu-Seok Hwang ◽  
Jung Yoon Yang ◽  
Yuji Son ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Epileptic Seizure ◽  
Neurological Disorders ◽  
Aminobutyric Acid ◽  
Oxygen Species ◽  
Gamma Aminobutyric Acid ◽  
Zebrafish Model ◽  
Neuroprotective Effects ◽  
Drug Discovery And Development ◽  
Spontaneous Seizures

Epilepsy is one of the most common neurological disorders, and it is characterized by spontaneous seizures. In a previous study, we identified 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as a novel anti-epileptic agent in chemically- or genetically-induced epileptic zebrafish and mouse models. In this study, we investigated the anti-epileptic effects of GM-90432 through neurochemical profiling-based approach to understand the neuroprotective mechanism in a pentylenetetrazole (PTZ)-induced epileptic seizure zebrafish model. GM-90432 effectively improved PTZ-induced epileptic behaviors via upregulation of 5-hydroxytryptamine, 17-β-estradiol, dihydrotestosterone, progesterone, 5α -dihydroprogesterone, and allopregnanolone levels, and downregulation of normetanephrine, gamma-aminobutyric acid, and cortisol levels in brain tissue. GM-90432 also had a protective effect against PTZ-induced oxidative stress and zebrafish death, suggesting that it exhibits biphasic neuroprotective effects via scavenging of reactive oxygen species and anti-epileptic activities in a zebrafish model. In conclusion, our results suggest that neurochemical profiling study could be used to better understand of anti-epileptic mechanism of GM-90432, potentially leading to new drug discovery and development of anti-seizure agents.

Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders

1999 ◽  
Vol 46 (5) ◽  
pp. 774-777 ◽  
Author(s):  
Albert Saiz ◽  
Francesc Graus ◽  
Josep Dalmau ◽  
Alex Pifarr� ◽  
Concepci� Mar�n ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Neurological Disorders ◽  
Brain Protein ◽  
Paraneoplastic Neurological Disorders

scholarly journals Age-Related Changes in Cerebrospinal Fluid γ-Aminobutyric Acid Concentration

1992 ◽  
Vol 30 (5) ◽  
Author(s):  
Haruhiko Takayama ◽  
Norio Ogawa ◽  
Mitsutoshi Yamamoto ◽  
Masato Asanuma ◽  
Hiroshi Hirata ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Acid Concentration ◽  
Aminobutyric Acid ◽  
Age Related ◽  
Age Related Changes

The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study

2021 ◽  
pp. 135245852110641
Author(s):  
Gaetano Bernardi ◽  
Tiziana Biagioli ◽  
Paola Malpassi ◽  
Teresa De Michele ◽  
Domizia Vecchio ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Neurological Disorders ◽  
Operating Characteristic ◽  
Neurological Diseases ◽  
Characteristic Curve ◽  
Oligoclonal Bands ◽  
Free Light Chains ◽  
Complementary Information ◽  
Combined Use

Background: Cerebrospinal fluid (CSF) free light chains (FLCs) can be an alternative assay to oligoclonal bands (OCBs) in inflammatory neurological disorders, but threshold has no consensus. Objective: To assess the diagnostic accuracy of CSF FLCs in multiple sclerosis (MS) and other neurological diseases. Methods: A total of 406 patients from five Italian centers. FLCs were measured in CSF and serum using Freelite MX assays on Optilite. Results: A total of 171 patients were diagnosed as MS, 154 non-inflammatory neurological diseases, 48 inflammatory central nervous system (CNS) diseases, and 33 peripheral neurological diseases. Both kFLC and λFLC indices were significantly higher in patients with MS compared to other groups ( p < 0.0001). The kFLC index ⩾ 6.4 is comparable to OCB for MS diagnosis (area under the receiver operating characteristic curve (AUC) = 0.876; sensitivity 83.6% vs 84.2%; specificity 88.5% vs 90.6%). λFLC index ⩾ 5 showed an AUC of 0.616, sensitivity of 33.3% and specificity of 90.6%. In all, 12/27 (44.4%) MS patients with negative OCB had kFLC index ⩾ 6.4. Interestingly, 37.5% of 24 patients with a single CSF IgG band showed high kFLC index and 12.5% positive λFLC index. Conclusion: Our findings support the diagnostic utility of FLC indices in MS and other CNS inflammatory disorders, suggesting a combined use of FLC and OCB to help clinicians with complementary information.

HPLC method for measurement of purine nucleotide degradation products in cerebrospinal fluid

1996 ◽  
Vol 42 (5) ◽  
pp. 756-760 ◽  
Author(s):  
L Kuracka ◽  
T Kalnovicová ◽  
B Líska ◽  
P Turcáni
Keyword(s):  
Cerebrospinal Fluid ◽  
Uric Acid ◽  
Neurological Disorders ◽  
Limit Of Detection ◽  
Degradation Products ◽  
Potassium Phosphate ◽  
Hplc Method ◽  
Potassium Phosphate Buffer ◽  
Nucleotide Degradation

Abstract We describe a convenient method for the separation and quantification of xanthine, hypoxanthine, and uric acid in 20 microL of cerebrospinal fluid (CSF) with use of HPLC and ultraviolet detection. The analysis is performed on a Sepharon SGX C18 column and the elution system consists of potassium phosphate buffer, pH 5.1, with 20 mL/L methanol. The lower limit of detection was 4 pmol for hypoxanthine and xanthine and 6 pmol for uric acid. Analytical recoveries of purine metabolites ranged from 98.6% to 102.9%. The intra- and interassay CVs were &lt;3%. The applicability of the method is illustrated with the determination of micromolar concentrations of xanthine, hypoxanthine, and uric acid in CSF samples obtained from 113 patients with various neurological disorders.

Sign in / Sign up

Export Citation Format

Share Document